會暢通訊(300578.SZ)擬1.5億元設立會暢超視 推進面向5G和超高清雲視訊佈局
格隆匯2月20日丨會暢通訊(300578.SZ)公佈,基於上海會暢通訊股份有限公司“雲+端+行業”的全產業鏈佈局,為加快公司推進面向下一代通信網絡和超高清雲視訊產業的發展戰略,公司擬以自有資金人民幣1.5億元在上海投資設立全資子公司上海會暢超視雲計算有限公司(以下簡稱“會暢超視”,最終名稱以工商登記為準)。本次投資是公司進一步推進面向5G和超高清雲視訊的戰略佈局,通過設立會暢超視導入公司的全產業鏈資源,更好的推進技術研發,業務落地和對外技術合作,增強公司核心競爭力,提升整體利潤水平。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.